Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World Journal of Gastrointestinal Pharmacology and Therapeutics. 2024;15(3):90757. doi: 10.4292/wjgpt.v15.i3.90757.
This open-label study evaluated the effectiveness and tolerability of GASTRAP® DIRECT, a formulation combining chitin-glucan and simethicone, in patients with irritable bowel syndrome (IBS). After 4 weeks of treatment, 67% of patients reported a significant reduction in abdominal pain, along with improvements in bloating, abdominal distension, and stool consistency. No serious adverse effects were observed, and 93% of participants rated the treatment’s tolerability as “good” or “very good.” These findings suggest that GASTRAP® DIRECT could be a promising treatment option for IBS management.
Keywords: Chitin-glucan, simethicone, irritable bowel syndrome, abdominal pain, bloating, stool consistency, GASTRAP® DIRECT